The Combination Of Olmesartan Plus Calcium Channel Blocker Is Superior To Olmesartan Plus Diuretic
348 views View
The Combination of Olmesartan Plus Calcium Channel Blocker is Superior To Olmesartan Plus Diuretic
Hypertension is associated with cardiovascular disease. Long term blood pressure control can be achieved by combination therapies. It is still unclear which combination therapy is safer and beneficial for the prevention of cardiovascular disease.
Angiotensin receptor blocker is often combined with a calcium channel blocker or a diuretic. But there is no clarification about the safer and effective combination.
Aim of the study
The aim of the study is to analyze the superiority of olmesartan plus calcium channel blocker to olmesartan plus diuretic in terms of safety and adherence.
The study included all the subjects aged 64-80 years with a history of cardiovascular disease or risk factors. A total of 5023 patients have completed the follow up.
The subjects included in the study were randomized to receive olmesartan either with calcium channel blocker or diuretic.
The subjects were followed up for three years and the end points were obtained. The end points of the study were the occurrence of the adverse effects and the discontinuity of the treatment.
Fischer’s exact test was used to compare the frequency rates of the adverse effects. The two groups were compared using Student’s t-test. All the statistical analysis was done using SAS 9.1 software.
Olmesartan plus calcium channel blocker group showed a lower incidence of adverse effects.
The continuation rate was lower in the olmesartan + diuretic group when compared to the olmesartan + calcium channel blocker.
The incidence of AE’s (Adverse events), SAE’s (Serious adverse events) were found to be higher in the olmesartan + diuretic group. The discontinuation of the treatment due to SAE’s was also higher in the olmesartan + calcium channel blocker group.
The study concludes that the combination therapy of olmesartan + calcium channel blocker is safe and effective for the treatment of hypertension.
Takao Saruta et al. Comparison of olmesartan combined with a calcium channel blocker or a diuretic in elderly hypertensive patients (COLM Study): safety and tolerability. Hypertens Res. 2015 Feb; 38(2): 132–136.
Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322201/
File size: 117 KB Downloads: 13